

Phase I study of S 78454 in the treatment of patients with acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndrome

Submission date 04/10/2013	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 09/12/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 22/01/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)

Scientific

Contact name

Prof Norbert Vey

Contact details

Institut Paoli Calmettes
232 Boulevard Sainte Marguerite
Marseille CEDEX 9
France
13273

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

CL1-78454-007

Study information

Scientific Title

Phase I dose escalation study of oral administration of S 78454 given as monotherapy in the treatment of patients with refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia or high or intermediary-2 risk myelodysplastic syndrome

Study objectives

To establish the safety profile and the recommended Phase II dose of S 78454.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

Study design

National multicentric dose escalation open Phase I study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details provided in the Interventions field to request a patient information sheet.

Health condition(s) or problem(s) studied

Acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndrome.

Interventions

Capsules containing 20 mg and 100 mg of S 78454 / Oral use / Treatment duration is at the discretion of the investigator

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

S 78454

Primary outcome measure

1. DLTs and MTDs at the end of cycle 1 - methods used: blood samples, physical examination, bone marrow samples, ECG
2. Safety profile at each visit

Secondary outcome measures

1. Pharmacokinetic and pharmacodynamic evaluations on cycle 1 and cycle 2 by blood sample
2. Response evaluation during the study by blood samples and bone marrow samples

Overall study start date

15/07/2012

Completion date

30/09/2015

Eligibility

Key inclusion criteria

1. Male or female patient aged > or equal to 18
2. Ability to swallow oral capsule(s)
3. Estimated life expectancy > 8 weeks
4. ECOG performance status < or equal to 2
5. Adequate renal and hepatic functions
6. Left ventricular ejection fraction within normal limits
7. Patients with AML as defined by WHO 2008 classification, excluding acute promyelocytic leukemia
8. Patients with high or intermediary risk (IPSS int-2) myelodysplastic syndrome (MDS) as defined by WHO 2008 classification and IPSS, who have failed hypomethylating therapy (5 azacytidine)
9. Patients with histologically or cytologically confirmed B-cell ALL as defined by WHO 2008 revised classification, excluding Philadelphia chromosome-positive (Ph+) ALL (or BCR-ABL+) and B-cell ALL 3 Burkitt like, who have failed conventional or investigational therapy

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

50 patients

Key exclusion criteria

1. Major surgery within previous 4 weeks
2. Diagnosis of acute promyelocytic leukemia, Philadelphia chromosomepositive (Ph+) ALL (or BCR-ABL+) or B-cell ALL 3 Burkitt like
3. Patients who have not recovered from toxicity of previous antileukaemic therapy, including grade < or equal to 1 non-haematologic toxicity
4. Any previous chemotherapy for AML within at least 2 weeks (or at least 5 half-life whichever is longer), except for hydroxyureas which must be stopped within 24 hours before starting the study drug)
5. Neutrophil growth factor stimulating agent (G-CSF) within previous one week
6. Last dose of biological therapy or immunotherapy agent (therapeutic or diagnostic) less than 7 days prior to the first study drug intake
7. Any concurrent treatment with anticoagulants (curative or preventive),
8. Any radiotherapy within previous 4 weeks (except for palliative radiotherapy at localised lesions)
9. Patients with history of allogeneic stem cell transplant of less than 6 months or with active graft versus host disease requiring immune suppressive therapy
10. Patients with active disseminated intravascular coagulation (DIC) (plasma fibrinogen <1 g/L)
11. Presence of heart disorders or clinically significant heart diseases
12. Pregnant or breastfeeding women, women of child-bearing potential without effective contraception

Date of first enrolment

15/07/2012

Date of final enrolment

17/10/2014

Locations

Countries of recruitment

France

Study participating centre

Institut Paoli Calmettes

Marseille CEDEX 9

France

13273

Sponsor information

Organisation

Pharmacyclics LLC (USA)

Sponsor details

999 East Arques Avenue

Sunnyvale

United States of America
94085

Sponsor type
Industry

Website
www.pharmacyclics.com

ROR
<https://ror.org/03hm8w204>

Funder(s)

Funder type
Industry

Funder Name
Pharmacyclics LLC (USA)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	15/01/2013	22/01/2019	Yes	No